Xenon Pharmaceuticals, Inc. (XENE)
35.34
-1.16
(-3.18%)
USD |
NASDAQ |
Oct 23, 16:00
35.30
-0.04
(-0.11%)
After-Hours: 20:00
Xenon Pharmaceuticals Enterprise Value : 2.495B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 2.495B |
| October 22, 2026 | 2.607B |
| October 21, 2026 | 2.554B |
| October 20, 2026 | 2.585B |
| October 19, 2026 | 2.470B |
| October 16, 2026 | 2.316B |
| October 15, 2026 | 2.397B |
| October 14, 2026 | 2.356B |
| October 13, 2026 | 2.406B |
| October 12, 2026 | 2.540B |
| October 09, 2026 | 2.601B |
| October 08, 2026 | 2.574B |
| October 07, 2026 | 2.599B |
| October 06, 2026 | 2.614B |
| October 05, 2026 | 2.711B |
| October 02, 2026 | 2.754B |
| October 01, 2026 | 2.842B |
| September 30, 2026 | 2.674B |
| September 29, 2026 | 2.680B |
| September 28, 2026 | 2.628B |
| September 25, 2026 | 2.650B |
| September 24, 2026 | 2.758B |
| September 23, 2026 | 2.613B |
| September 22, 2026 | 2.858B |
| September 21, 2026 | 2.848B |
| Date | Value |
|---|---|
| September 18, 2026 | 2.922B |
| September 17, 2026 | 4.625B |
| September 16, 2026 | 4.567B |
| September 15, 2026 | 4.521B |
| September 14, 2026 | 4.706B |
| September 11, 2026 | 4.750B |
| September 10, 2026 | 4.765B |
| September 09, 2026 | 4.782B |
| September 08, 2026 | 4.837B |
| September 04, 2026 | 4.857B |
| September 03, 2026 | 4.920B |
| September 02, 2026 | 4.896B |
| September 01, 2026 | 4.881B |
| August 31, 2026 | 4.902B |
| August 28, 2026 | 4.880B |
| August 27, 2026 | 5.068B |
| August 26, 2026 | 5.248B |
| August 25, 2026 | 4.922B |
| August 24, 2026 | 4.935B |
| August 21, 2026 | 4.955B |
| August 20, 2026 | 4.855B |
| August 19, 2026 | 5.105B |
| August 18, 2026 | 5.189B |
| August 17, 2026 | 5.109B |
| August 14, 2026 | 5.108B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Psyence Biomedical Ltd. | -- |
| Aurinia Pharmaceuticals, Inc. | 1.862B |
| enGene Therapeutics, Inc. | -128.59M |
| Medicus Pharma Ltd. | 155.00M |
| ACADIA Pharmaceuticals, Inc. | 2.514B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -110.74M |
| Total Expenses (Quarterly) | 110.74M |
| EPS Diluted (Quarterly) | -1.112 |
| Earnings Yield | -13.42% |
| Normalized Earnings Yield | -13.42 |